Skip to main content
Figure 4 | BMC Cancer

Figure 4

From: Troglitazone suppresses telomerase activity independently of PPARγ in estrogen-receptor negative breast cancer cells

Figure 4

Troglitazone does not cause cell toxicity and does not induce apoptosis in MDA-MB-231 cells. A) MDA-MB-231 cells were treated with various concentrations of troglitazone (0, 10, 20, 50, 100, 250, 500, 1000 μM) for 24 or 48 hours and cell toxicity was determined by the MTS assay. All data were normalized against the DMSO treated control group in the respective treatment. B) Cells were exposed to 20 μM troglitazone for 3 days and cell viability was measured using automated Vi-CELL. Values expressed as percent survival of DMSO treated controls. Data were collected from three experiments performed in triplicate. WT, DMSO; T20, 20 μM troglitazone. C) Equal amounts of MDA-MB-231 cell lysate from DMSO and treated cells with 20 μM troglitazone (Tro 20 μM) for 24 hours were subjected to western blot analysis to determine the protein levels of caspase-3 and PARP. No differences were found between control and troglitazone treated cells. The western blots shown are representative of three separate experiments.

Back to article page